Australian Office Accepts Dermata’s Bioneedle Dermal Filler Patent, Issues in 3 Months
Dermata’s Australian patent application for its topical dermal filler program (application No. 2020315876) has been accepted and will automatically issue in three months barring opposition. This expands Dermata’s global IP alongside existing BDS patents in the US, Australia and Japan for botulinum toxin treatments.
1. Patent Acceptance Details
The Australian Patent Office has accepted Dermata’s patent application No. 2020315876 for topical delivery of dermal fillers using the Bioneedle Delivery System. The patent will automatically issue three months after acceptance unless a third party files an opposition.
2. Bioneedle Delivery System Technology
BDS employs wild-harvested Spongilla lacustris to create microchannels that enable non-invasive, topical administration of macromolecules such as dermal fillers, potentially reducing injection pain and broadening aesthetic treatment options.
3. Expanding Global IP Portfolio
This marks Dermata’s first patent for dermal filler applications and complements already granted BDS patents in the US, Australia and Japan covering botulinum toxin for hyperhidrosis, bolstering the company’s competitive moat.
4. Commercialization and Pipeline
Following a strategic pivot to direct-to-consumer skincare, Dermata plans to launch its first BDS-based skin refresh and acne treatment products in mid-2026, leveraging its growing IP to support market entry and adoption.